Analysts downgrade revenue estimates for next year and reduc...
Analysts downgrade revenue estimates for next year and reduce loss estimates. The company's revenue is expected to decline by 92% annually by end of 2024, a shift from historical growth of 47% over the last five years. Fate Therapeutics is expected to lag the wider industry.
US$7.53 - That's What Analysts Think Fate Therapeutics, Inc. (NASDAQ:FATE) Is Worth After These Results
Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates.
Read more
Comment
Sign in to post a comment